Applications of Myrtucommuacetalone in medicines treating renal insufficiency

A technology for renal insufficiency, applied in the application field of Myrtucommuacetalone in the treatment of renal insufficiency, can solve the problems of large toxic and side effects, high price, dependence on imports, etc., and achieves the effect of strong therapeutic activity and outstanding substantive characteristics.

Inactive Publication Date: 2014-04-09
鄄城县人民医院
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of Myrtucommuacetalone in medicines treating renal insufficiency
  • Applications of Myrtucommuacetalone in medicines treating renal insufficiency
  • Applications of Myrtucommuacetalone in medicines treating renal insufficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of the compound Myrtucommuacetalone tablet involved in the present invention:

[0016] Take 5 grams of the compound Myrtucommuacetalone, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0017] Embodiment 2: the preparation of the compound Myrtucommuacetalone capsule involved in the present invention:

[0018] Get 5 grams of compound Myrtucommuacetalone, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0020] Experimental example 1: Study on the effect of Myrtucommuacetalone on the acute kidney injury model in mice

[0021] 1. Establishment of cisplatin-induced acute kidney injury model in mice: Male Kunming KM mice, 16-18 g, were randomly divided into solvent control group, cisplatin model group, and administration group according to body weight, a total of 6 groups, each group 8 only. The control group was intraperitoneally injected with normal saline, and cisplatin was dissolved in normal saline and injected intraperitoneally at 7 mg / kg. The compound of the present invention was orally administered 2 days before the injection of cisplatin, once a day, for a total of five times; the positive control drug, Benazepril (K), was orally administered at the same time as the injection of cisplatin, once a day, for a total of five times. Three times of administration (administration started 2 days before the injection of cisplatin is less effective than simultaneous administratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of Myrtucommuacetalone in medicines preventing and / or treating renal insufficiency, belongs to the technical field of new applications of medicines, and is disclosed for the first time. The skeleton type belongs to a brand new skeleton type. Myrtucommuacetalone has strong inhibition activity to renal insufficiency, has outstanding substantive features and has substantial progress in controlling renal insufficiency obviously.

Description

technical field [0001] The present invention relates to a new application of compound Myrtucommuacetalone, in particular to the application of Myrtucommuacetalone in the preparation of drugs for treating renal insufficiency. Background technique [0002] Chronic kidney disease (including various chronic nephritis, diabetic nephropathy and hypertensive renal damage, etc.) is the most common chronic refractory disease. Renal tissue lesions will gradually progress from early lesions to advanced lesions of glomerulosclerosis and / or interrenal fibrosis. If not treated effectively, it will eventually lead to chronic renal insufficiency and irreversible end-stage renal failure (ie uremia). Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects. Such as causing some patients hyperkalemia, insurmountable cough, blood pressure lowering effect is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P13/12
Inventor 陈军
Owner 鄄城县人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap